Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine. […]
November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine. […]
The Stop TB Partnership’s Global Drug Facility (GDF) has added the anti-TB drug pretomanid to its catalog of TB medicines.
NEW YORK and MUMBAI (October 28, 2019)—Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals Limited a non-exclusive license to
The public health progress in the World Health Organization’s Global Tuberculosis (TB) Report 2019 this year can be found in
TB Alliance applauds the Stop TB Partnership’s TB REACH program for investing in efforts to combat tuberculosis (TB). The $15.4
NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S.
On July 28th in South Africa, more than 100 members of the TB research community marched under the Louder than
July 18, 2019—Tuberculosis (TB) is the leading infectious cause of death worldwide and the number one cause of death among
NEW YORK (June 25, 2019)—TB Alliance today announced the appointment of Eugene Sun, MD to the position of Senior Vice
The G20’s top health and health financing experts will assemble in Tokyo on the eve of the Osaka G20 heads